Equid herpesvirus type 1 (EHV-1) was shown to use an unusual receptor for cellular entry -MHC-I molecules. Here, we demonstrated that the closely related EHV, EHV-4, also uses this strategy for cellular invasion, both in equine cells in culture and in the heterologous, nonpermissive murine mastocytoma cell line (P815) after stable transfection with horse MHC-I genes. Using a panel of P815 cell lines transfected with individual horse MHC-I genes, we provided support for the hypothesis that EHV-1 and EHV-4 target classical polymorphic MHC-I molecules as viral entry receptors. All known equine MHC-I molecules from the two principal classical polymorphic loci specify alanine at position 173 (A173), whilst other MHC-I loci encoded different amino acids at this position and did not permit viral entry. Site-directed mutagenesis of position 173 diminished or enhanced viral entry, depending upon the initial amino acid. However, there were other, as yet undefined, constraints to this process: MHC-I genes from two non-classical loci carried A173 but did not enable viral entry in P815 transfectants. Our study suggested that the capacity to bind MHC-I molecules arose in the common ancestor of EHV-1 and EHV-4. The widespread occurrence of A173 in classical polymorphic horse MHC-I molecules indicated that horses of most MHC haplotypes should be susceptible to infection via this entry portal.
INTRODUCTION
MHC-I molecules present peptides derived from intracellular antigens to cytotoxic T-lymphocytes and function in immune surveillance in the effector phase of immune responses (Ma et al., 2013) . In horses, over 50 MHC-I sequences have been identified (Tallmadge et al., 2010) and as many as seven MHC class I genes encoded by a single horse MHC haplotype can be expressed in lymphocytes (Tallmadge et al., 2005) . The genes of two MHC-I loci have characteristics of classical, polymorphic peptide-presenting molecules, whilst several other loci appear more like the non-classical, pauci-polymorphic loci of humans and mice (Tallmadge et al., 2010) . The equine MHC-I region is further distinguished by haplotypes in which the number and nature of class I genes varies considerably, perhaps indicating differences in evolutionary history or a more rapid rate of MHC-I gene duplication between horses and other species (Tallmadge et al., 2010) .
For many reasons, MHC-I molecules seem an unlikely choice as a viral entry receptor. Although they are membrane-bound proteins present on virtually all somatic cells, MHC-I molecules are among the most polymorphic of all mammalian proteins. Some MHC loci have hundreds of alleles and the alleles can differ by 10-25 % of their amino acid composition (Gilcrease, 2007; Tallmadge et al., 2010) . A role as viral entry receptor was proposed originally, but then rejected, for coxsackievirus A9 (Crandell et al., 1988; Ma et al., 2013) . The involvement of human HLA-C MHC-I molecules in viral entry has been reported for coronavirus infection in humans (Crandell et al., 1988) .
Recently, two independent studies identified three equine MHC-I molecules that can act as a receptor for equid herpesvirus type 1 (EHV-1) entry into equine cells (Kurtz et al., 2010; Sasaki et al., 2011a) . The MHC-I molecule interacts with the EHV-1 glycoprotein D (gD), and, furthermore, aa 173 in the a2 domain of the equine MHC-I heavy chain has been shown to be an important determinant in the efficiency of EHV-1 entry (Sasaki et al., 2011b) .
EHV-4, like EHV-1, is a member of the Alphaherpesvirinae subfamily, genus Varicellovirus (Davison et al., 2009; Ma et al., 2013) . It is endemic in horse populations throughout the world and causes significant economic losses to the equine industry. The virus can spread from animal to animal by the respiratory route, with clinical signs confined mainly to the upper respiratory system. Cell-associated viraemia is not a common feature of EHV-4 infection. Consequently, EHV-4 is only very rarely associated with abortion and neurological disorders (Matsumura et al., 1992; Osterrieder & Van de Walle, 2010; Patel & Heldens, 2005; Verheyen et al., 1998) . This restricted pathogenicity is reflected in the limited host range of EHV-4: the virus replicates poorly in only a few non-equine cell lines when compared with its close relative EHV-1 (Azab & Osterrieder, 2012) .
As is the case with other alphaherpesviruses, EHV-4 encodes at least 11 glycoproteins, all of which are present in the virus envelope (Telford et al., 1998) . Due to their roles in virus attachment, binding, fusion and cell-to-cell spread, herpesvirus glycoproteins are important determinants of infectivity, pathogenicity and cellular host tropism (Azab & Osterrieder, 2012; Spear, 1985; Spear & Longnecker, 2003) . EHV-4 initially attaches to the cell surface through an interaction between viral gC and cellular heparan sulphate (Azab et al., 2010) . However, this interaction is not sufficient to trigger virus entry and another glycoprotein, gD, is needed for stable binding to cellular receptors and triggering the process of entry. Recently, we have shown that gD plays an important role in the cellular host range of EHV-4 as well as EHV-1 (Azab & Osterrieder, 2012) , but there are no data available regarding the cellular receptors used by EHV-4 to gain entry into the cells.
In this study, we investigated the ability of EHV-4 to use MHC-I as an entry receptor to infect equine cells. We provided evidence that MHC-I molecules serve as specific cell receptors of EHV-4. We also determined that EHV-1 and EHV-4 use a restricted set of equine MHC-I molecules for viral entry.
RESULTS

EHV-4 uses MHC-I as an entry receptor
Previous reports identified equine MHC-I molecules as cellular entry receptors for EHV-1, the close relative of EHV-4 (Kurtz et al., 2010; Sasaki et al., 2011a) . We hypothesized that EHV-4 may enter equine cells using the same receptor because of the high genetic similarity between the two viruses (Telford et al., 1998) . In preliminary studies we tested the murine B78H1 cell line stably transfected with equine MHC-I for entry of EHV-1 and EHV-4. The B78H1 parent cells had been shown to be resistant to EHV-1 before being transduced with equine MHC-I (Kurtz et al., 2010) . Both EHV-1 and EHV-4 were able to enter cells transgenic for equine MHC-I (B9C8 and B78HC2), but not the native parent cell line (Fig. 1a, c) . We extended this finding by testing the ability of EHV-1 and EHV-4 to enter mouse P815 mastocytoma cells that were stably transfected with previously untested MHC-I genes from the ELA-A2 haplotype: gene 16*00101 (also referred to as 2.16) and an MHC-I molecule that was termed 2.X (Tallmadge et al., 2010) . Both MHC-I molecules supported viral entry for EHV-1 and EHV-4, but neither virus could enter the WT P815 cells (Fig. 1b, d ).
EHV-4 infection of equine cells is MHC-I dependent
To further assess the role of equine MHC-I molecules in EHV-4 entry, a blocking assay using specific anti-MHC-I antibodies (H58A and/or CZ3) was performed. Preincubation of P815 cells expressing the ELA-A2.16 equine MHC-I with antibodies blocking equine MHC-I reduced the rate of infection of EHV-4 in a dose-dependent manner (Fig. 2a, b) .
EHV-4 can be readily propagated in several primary equine cell lines (Azab & Osterrieder, 2012; Maeda et al., 2007) . Here, we investigated the role of equine MHC-I molecules during the entry of EHV-4 into foetal horse kidney (FHK), equine dermal (ED or APH) and endothelial (EC) cells. First, expression of MHC-I on the surface of these cells using anti-MHC-I H58A antibody was confirmed using flow cytometry (Fig. 2c, left panel) . Then, we used the same anti-MHC-I antibody to block MHC-I molecules on the surface of equine cells to investigate their role during virus entry. Flow cytometry showed that H58A treatment significantly inhibited EHV-4 entry into primary equine cell lines compared with the mock-treated cells (Fig. 2c , right panel).
We further tested whether EHV-4 could utilize cell-surface MHC-I expressed on cells of non-equine origin that could be infected with EHV-4. We tested human (HeLa), bovine (MDBK), and non-human primate (Vero) cell lines. Whilst MHC-I was significantly expressed on the surface of all three cell lines (Fig. 2d, left panel) , the anti-MHC-I H58A antibody failed (P.0.05) to block the entry of EHV-4 into these cells (Fig. 2d, right panel) . From these results we concluded that equine MHC-I molecules were essential for EHV-4 entry into equine cells only and that EHV-4 may use a different cellular receptor(s) to enter non-equine cells or that the blocking antibody worked less well in the presence of xenogenic (mouse) b 2 -microglobulin.
Interaction between EHV-4 gD (gD4) and equine MHC-I is essential for virus entry
The gDs of alphaherpesviruses are known or discussed to be essential for virus binding to cell-surface receptors -an interaction that triggers virus entry (Campadelli-Fiume et al., 2012; Spear & Longnecker, 2003) . A previous report indicated that EHV-1 gD acts as a ligand for MHC-I on the surface of equine cells (Sasaki et al., 2011a) . To investigate the role of EHV-4 gD (gD4) in virus entry through binding to MHC-I, we generated soluble gD4 consisting of the extracellular domain of gD4 fused to a C-terminal tag composed of the Fc region of human IgG, followed by a polyhistidine motif (His 6 ) (gD4-Fc-His). We next analysed the direct interaction between gD4 and MHC-I expressed on the surface of P815_2.16. Our results showed that gD4 bound to P815 cells expressing equine MHC-I, P815_2.16, but not the parental line (Fig. 3a) .
We next analysed the ability of gD4-Fc-His and anti-gD4 antibody to block EHV-4 entry into ED and P815_2.16 cells, and we measured the outcome by using flow cytometry. Our results showed that soluble gD4 (Fig. 3b) as well as gD4-specific antibodies ( Fig. 4a ) significantly blocked EHV-4 entry. Incubation of EHV-1, used as a negative control in this experiment, with anti-gD4 antibody at the same dilutions did not affect the ability of the virus to enter P815_2.16 (data not shown). The data suggested that EHV-4 gD was directly involved in EHV-4 entry through equine MHC-I receptors.
We further explored the role of gD in virus entry into equine cells. The entry of both EHV-1 bearing gD4 (EHV1gD4) and EHV-4 bearing gD1 (EHV-4gD1) was inhibited significantly (P,0.05) after blocking MHC-I expression on the surface of ED and FHK cells (Fig. 4b, c) , suggesting that both gD1 and gD4 can bind to the same receptor (MHC-I) to facilitate the entry of EHV-1 and EHV-4. We concluded from our data that EHV-4 gD is a ligand for equine MHC-I and that their interaction is important for virus entry.
EHV-1 and EHV-4 can enter P815 cells transfected with classical polymorphic horse MHC-I genes from four common horse haplotypes
Previous reports have shown that EHV-1 can be readily propagated in murine cells expressing different equine MHC-I molecules (Kurtz et al., 2010; Sasaki et al., 2011a) . Furthermore, it was suggested that the amino acid residue alanine at position 173 of the equine MHC-I heavy chain molecule determines the efficiency of EHV-1 entry (Sasaki et al., 2011b) . We examined the amino acids at position 173 in horse MHC-I molecules from different MHC haplotypes and different MHC loci (Fig. 5a ). We noticed that all known alleles of the two major polymorphic MHC-I loci, locus 1 and locus 16 (Tallmadge et al., 2010) , specify alanine at position 173. We constructed seven stable P815 transfectants carrying genes of locus 1 or 16 from five common equine MHC haplotypes, ELA-A2, ELA-A3, ELA-A5, ELA-A9 and ELA-A10 (named here as P815_2.16, P815_3.1, P815_9.1, P815_9.16 and P815_10.1), as well as two other classical MHC-I genes specifying A173 (P815_2.X and P815_5.X), and tested the lines for susceptibility to ) At 24 h post-infection, the indicated equine or non-equine cells were collected and the percentage of infected cells was determined by flow cytometry. As controls, cells were incubated with irrelevant mAbs of the same IgG isotype. *P,0.05 (one-way ANOVA). MHC-I expression was determined by flow cytometry. Histograms (left panels) and percentages (right panels) are shown. *P,0.05, **P,0.01 (Student's t-test). The rate of infection in the absence of anti-MHC-I antibody was set to 100 %. All data represent the mean±SD of three independent experiments. infection with EHV-1 and EHV-4. Our results showed that all seven cell lines were susceptible to infection with both EHV-1 and EHV-4 (Fig. 5b) .
Equine MHC-I molecules from most MHC loci do not support entry of EHV-1 or EHV-4 ELA-A3 is the best-characterized MHC haplotype of horses (Tallmadge et al., 2010) . The ELA-A3 haplotype expresses at least seven full-length MHC-I genes from distinct loci (Tallmadge et al., 2005) . To contrast with the experiment that tested polymorphic MHC-I molecules from several haplotypes, we created seven stable transfected P815 lines, each carrying a different MHC-I gene of the ELA-A3 haplotype (named here as P815_3.1-P815_3.7). Surprisingly, only the classical polymorphic ELA-A3.1 transfectant supported entry of EHV-1 and EHV-4 to the cell lines. No virus entry was detected in any of the other transfectants, even though two of the MHC molecules (A3.2 and A3.7) specify alanine at position 173 (Fig. 5c ).
Alanine at position 173 of horse MHC-I molecules is essential, but not sufficient, to allow viral entry To further investigate the importance of alanine at residue 173 in virus entry, we mutated alanine into threonine in three susceptible (P815_2.16, P815_2.X and P815_3.1) and threonine to alanine in two resistant (P815_3.4 and P815_10.18) cell lines. This change did not alter cellsurface expression of these molecules as assessed by immunofluorescence flow cytometry using anti-MHC-I mAb (data not shown). As expected, the change to threonine in the permissive MHC-I molecules resulted in decreased capacity to support both EHV-1 and EHV-4 entry, whilst the mutation to alanine in the resistant MHC-I molecule increased that same capacity (Fig. 6) . The rate of infection of parental viruses was set to 100 %. All data represent the mean±SD of three independent experiments. **P,0.01 (Student's t-test).
Taken together, the data suggested that alanine at residue 173 was indeed important for virus binding and entry as replacing this amino acid with any other amino acid rendered the cells resistant to virus entry. However, alanine is not the only virus entry determinant, and there must be residues at other locations in the molecule that promote the interaction between virus and host MHC-I molecules to allow virus entry.
DISCUSSION
In this study, we demonstrate further that an important equine pathogen, EHV-4, uses equine MHC-I molecules as a receptor, both in heterologous (murine) cells stably expressing equine MHC-I and in horse cell lines. EHV-4, therefore, behaves identically to its close relative EHV-1 with respect to cellular entry through equine MHC-I. We also show that EHV-4 gD binds to equine MHC-I and is able to block interaction of virus with its receptor using a soluble form of the viral glycoprotein as well as gD4-or MHC-I-specific antibodies. Therefore, our data suggest that this viral entry strategy likely arose in the common ancestor of EHV-1 and EHV-4.
We provide evidence that structural factors other than A173 on the horse MHC-I molecule have a major influence on virus binding. A173 appears to be necessary, but not sufficient, for this binding and subsequent entry. Horse MHC-I molecules are encoded by a diverse set of genes in the horse MHC haplotypes that have been studied in detail (Tallmadge et al., 2005 (Tallmadge et al., , 2010 . Horse MHC haplotypes include genes at polymorphic classical MHC-I loci, termed 1 or 16, and some haplotypes carry both loci. The known alleles at both of these loci all have alanine at position 173 and all classical molecules that have been tested permit EHV entry. In contrast, each MHC haplotype also carries a variable number of other expressed MHC-I genes. Some of these genes have been termed non-classical because of their lack of polymorphism and other structural features (Ellis et al., 1995) . Other MHC-I genes are not clustered with other class I genes and thus appear to be the only representatives of their loci. Still other loci are expressed in most horses, but have unusual polymorphism characteristics. The function of these genes is not known at present, but inspection of these genes reveals that most of the loci other than 1 and 16 carry alleles with amino acids other than alanine at position 173, and we show here that these genes do not support EHV entry (Table 1) . Therefore, we currently conclude from data reported here and in previous publications that EHV-1 and EHV-4 target a domain of classical polymorphic equine MHC-I molecules that involves alanine at position 173 and other as-yet-unidentified structures. However, all MHC-I molecules that do not specify an alanine at residue 173 are highly resistant to EHV-1 and EHV-4 entry, regardless of whether the amino acid substitution has a hydrophobic or hydrophilic side chain -a result that indicates that the hydrophobicity of the amino acid at residue 173 has no role in deciding the ability of MHC-I to allow virus entry as was proposed previously (Sasaki et al., 2011b) .
The envelope glycoprotein gD is conserved among almost all alphaherpesviruses and it has the ability to bind different receptors expressed on several cell types (Campadelli-Fiume & Menotti, 2007; Connolly et al., 2011) . Recently, we showed that differential use of receptors conferred an extended cellular host range for EHV-1; however, EHV-4 gD has a limited range of receptors that it can bind to, which consequently reduces the host range of the virus compared with EHV-1 (Azab & Osterrieder, 2012) . Here, we could prove that MHC-I acts as an entry receptor for EHV-4 into equine cells only and we were unable to block entry of the virus into non-equine cells. This result may indicate that, like EHV-1, EHV-4 utilizes a different receptor(s) to infect non-equine cells. Although EHV-4 has presumably evolved to infect equine cells, on the cell types tested, alternative receptors may be present on the non-equine but not the equine examples.
The finding that EHV-1 and EHV-4 use the same cell receptor to infect equine cells ( even more difficult to explain the strikingly different pathogenicity of both viruses. In vivo, EHV-1 can enter and productively infect at least three distinct cell populations (epithelial cells, mononuclear cells and ECs), whilst EHV-4 is thought to be restricted mainly to epithelial cells (Osterrieder & Van de Walle, 2010) . As MHC-I molecules are expressed on virtually all somatic cells (David-Watine et al., 1990) , the distribution of MHC-I may not have a direct correlation with EHV-1 or EHV-4 cell tropism (Sasaki et al., 2011a) . Our findings therefore raise the question as to why EHV-4 is unable to establish a systemic infection in its natural host. In all cases, the reason should not be related to ligand/receptor binding; rather, it should be post-binding or post-entry events. However, the underlying mechanism(s) has yet to be elucidated.
In conclusion, this work advances our knowledge of the use of MHC-I molecules as cellular entry receptors by EHVs. However, much remains to be learned about this novel strategy for viral entry, especially pertaining to steps that follow stable receptor binding and virus uptake into the cytoplasm, and the ensuing delivery of viral nucleic acids into the host cell nucleus.
METHODS
Viruses and cell lines. An EHV-4 infectious bacterial artificial chromosome clone (Azab et al., 2009) , EHV-1 strain L11Dgp2 (Rudolph et al., 2002) , and EHV-1 mutants harbouring gD4 (EHV1gD4) and EHV-4gD1 (Azab & Osterrieder, 2012) were used in this study. All viruses expressed EGFP for rapid identification of infected cells.
FHK (kindly provided by Dr V. Svansson, University of Iceland), ED, APH, HeLa, Vero, MDBK and mouse mastocytoma (P815) cell lines were propagated in Dulbecco's modified Eagle's medium (DMEM; Biochrom) supplemented with 10 % FBS (Biochrom), 100 U penicillin ml
21
, and 100 mg streptomycin ml
. Cells were maintained at 37 uC with 5 % CO 2 . Murine melanoma B78H1 as well as B9C8 and B78HC2 cells, expressing equine MHC-I, were propagated in DMEM supplemented with 10 % FBS. Primary equine vascular ECs from carotid arteries of healthy horses (kindly provided by Dr Udeni Balasuriya, University of Kentucky) were propagated in DMEM supplemented with 10 % FBS.
Cloning of equine MHC-I genes. Full-length MHC-I genes were amplified from lymphocytes of horses known to carry specific MHC-I serotypes using generic primers located in the 59-and 39-untranslated regions or locus-specific primers (Table S1 , available in the online Supplementary Material). Products were amplified using Iproof HighFidelity DNA Polymerase (Bio-Rad) with the following conditions: one cycle of 98 uC for 3 min, 35 cycles of 98 uC for 10s, 60 uC for 20s, and 72 uC for 30s, and one cycle of 72 uC for 10 min. Bands of the correct size were excised and purified using the QIAquick Gel Purification kit (Qiagen) following the manufacturer's protocol. Purified blunt-ended DNA was cloned into the PCR4 Blunt TOPO vector (Invitrogen). Clones containing inserts of the correct size were sequenced at the Cornell University Life Sciences Genomics Core facility. Sequences were analysed with Geneious software (Biomatters).
MHC-I clones selected to be used in future experiments were modified with primers specific for each gene containing an XbaI site in the forward primer and an EcoRI site in the reverse primer (Table  S1 ). PCR amplifications were carried out as described above and products were confirmed by sequencing. Selected clones were digested with XbaI and EcoRI, gel purified, and directionally cloned into pCDNA3.1 (Invitrogen). Following another round of confirmation by sequencing, appropriate clones were digested with PvuI and stably transfected into P815 cells.
Selected clones carrying an alanine or threonine residue at position 173 were mutated via PCR to change alanine residues to threonine or vice versa. Primary PCRs used plasmid templates described above to amplify two overlapping fragments: a 59 fragment containing a modified base near the 39 end and a 39 fragment containing a modified base near the 59 end. Fragments were gel electrophoresed, purified and used as templates in the following PCRs with restrictionenzyme-modified primers described previously. After confirmation by sequencing, clones were digested with XbaI and EcoRI, and directionally cloned into pCDNA3.1 as described above. (Lonza) . At 24 h after transfection, 1 mg Geneticin ml 21 (Invitrogen) was added to cultures. Cells were maintained in medium containing Geneticin for 4 weeks, after which they were cultured in standard medium. Surface expression of horse MHC-I protein was assessed by flow cytometry using the anti-equine MHC-I mAb CZ3 (Donaldson et al., 1988) . Limiting dilution techniques were used to create clonal cell lines, each expressing a unique horse MHC-I protein.
Expression of recombinant gD. Recombinant EHV-4 gD was produced using a Bac-to-Bac baculovirus expression system (Invitrogen) as described previously (Engel et al., 2012) . The extracellular domain of gD4 (primers are listed in Table S1 ) was expressed as a secreted protein, gD4-Fc-His, bearing a C-terminal tag composed of human IgG-Fc and His 6 , and purified by Protein G affinity chromatography (Engel et al., 2012) .
Blocking assays. For blocking cell-surface MHC-I molecules, a total of 2610 4 cells were seeded in 96-well plates. Before addition of antibodies, maintenance medium was removed and all cells were washed with PBS containing 2 % FBS. Twofold dilutions of the anti-MHC-I mAb H58A (VMRD) or the anti-equine MHC-I mAb CZ3 were made, and 25 ml of each dilution was added to the cells in duplicate. In another experiment, cells were incubated with anti-MHC-I H58A antibody (20 mg ml 21 ). After 1 h incubation at 37 uC, the cells were washed and infected with EHV-4, EHV-1, EHV-1gD4 or EHV-4gD1 (m.o.i. 5) for 24 h. The fluorescence intensity of infected cells was measured using flow cytometry.
For blocking virus entry, EHV-4 was incubated with anti-gD4 mAb (kindly provided by Dr Jules Minke, Merial, Lyon, France) for 1 h at 37 uC. In another experiment, cells were incubated with gD4-Fc-His or Fc-His proteins (20 mg ml
) for 1 h at 37 uC. The virus was then added to the cells and incubated for 1 h at 37 uC. Cells were then washed and maintained in fresh growth medium, and infection was allowed to proceed for another 24 h. Viral entry was analysed by counting GFP-positive cells using flow cytometry.
Virus infection assay. Cells were infected with either EHV-4 or EHV-1 (m.o.i. 5) for 1 h at 37 uC. Cells were then washed and incubated with fresh growth medium, and the infection was allowed to proceed for another 24 h. GFP-positive cells were inspected by using an inverted fluorescence microscope (Zeiss Axiovert 100) and photographed with an Axiocam CCD camera (Zeiss) for each virus. ) for 1 h at room temperature. An isotype control mouse IgG (2 mg ml 21 ) was also included as a control. After two washes with PBS, cells were incubated with Alexa Fluor 488-labelled goat anti-mouse IgG (Invitrogen; 1/500 dilution) for 1 h at room temperature. After a final wash, 10 000 cells were analysed with a FACSCalibur flow cytometer (BD Biosciences) and the intensity of fluorescence was analysed using FlowJo software (Treestar).
For binding assays, cells were incubated with gD4-Fc-His or Fc-His proteins (10 mg ml 21 ) at 37 uC for 1 h, stained with anti-human Fc-FITC (Jackson ImmunoResearch), and analysed by flow cytometry.
For infection experiments, cells were seeded in 24-well plates and infected with EHV-4, EHV-1, EHV-1gD4 or EHV-4gD1 (m.o.i. 5). After 24 h, cells were collected and washed twice with PBS. After centrifugation, cells were resuspended in PBS supplemented with propidium iodide (Molecular Probes) at a final concentration of 10 mg ml 21 and the intensity of fluorescence of 10 000 GFP-positive cells was analysed to determine the percentage of infected cells.
Statistical analysis. Prism software (Graphpad), one-way ANOVA and Student's t-test were used to test for statistically significant differences. Data given are mean±SD.
